GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Nicholson AG, Chansky K, Crowley J, et al. The international association for the study of lung cancer lung cancer staging project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(3):300–311. doi:10.1016/j.jtho.2015.10.008
   PubMed Web of Science ®Google Scholar
• Wang S, Zimmermann S, Parikh K, Mansfield AS, Adjei AA. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599–1622. doi:10.1016/j.mayocp.2019.01.034
   PubMed Web of Science ®Google Scholar
• Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12(9):1096–1104. doi:10.1634/theoncologist.12-9-1096
   PubMed Web of Science ®Google Scholar
• Reck M, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase 2 trial. Ann Oncol. 2013;24(1):75–83. doi:10.1093/annonc/mds213
   PubMed Web of Science ®Google Scholar
• Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–1110. doi:10.1038/ng.2396
   PubMed Web of Science ®Google Scholar
• Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14(9):549–561. doi:10.1038/nrclinonc.2017.71
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Callahan MK, Awad MM, et al. Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer. Cancer Cell. 2018;33(5):853–861.e4. doi:10.1016/j.ccell.2018.04.001
   PubMed Web of Science ®Google Scholar
• Ott PA, Bang Y-J, Piha-Paul SA, et al. T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol. 2019;37(4):318–327. doi:10.1200/JCO.2018.78.2276
   PubMed Web of Science ®Google Scholar
• Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi:10.1172/JCI91190
   PubMed Web of Science ®Google Scholar
• Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. J Hematol Oncol. 2019;12(1):67. doi:10.1186/s13045-019-0753-2
   PubMedGoogle Scholar
• Liu SV, Horn L, Mok T, et al. 1781MO IMpower133: characterisation of long-term survivors treated first-line with chemotherapy±atezolizumab in extensive-stage small cell lung cancer. Ann Oncol. 2020;31:S1032–S1033. doi:10.1016/j.annonc.2020.08.1543
   Web of Science ®Google Scholar
• Rudin CM, Awad MM, Navarro A, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, Phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–2379. doi:10.1200/JCO.20.00793
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, Phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Pujol J-L, Greillier L, Audigier-Valette C, et al. A randomized non-comparative phase II study of anti-programmed cell death-ligand 1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer: results from the IFCT-1603 trial. J Thorac Oncol. 2019;14(5):903–913. doi:10.1016/j.jtho.2019.01.008
   PubMed Web of Science ®Google Scholar
• Lin A, Qiu Z, Zhang J, Luo P. Effect of NCOR1 mutations on immune microenvironment and efficacy of immune checkpoint inhibitors in patient with bladder cancer. Front Immunol. 2021;12:630773. doi:10.3389/fimmu.2021.630773
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Hizukuri Y, Yamashiro K, et al. Guanylate-binding protein 5 is a marker of interferon-γ-induced classically activated macrophages. Clin Transl Immunol. 2016;5(11):e111. doi:10.1038/cti.2016.59
   PubMedGoogle Scholar
• Blakely AM, Matoso A, Patil PA, et al. Role of immune microenvironment in gastrointestinal stromal tumours. Histopathology. 2018;72(3):405–413. doi:10.1111/his.13382
   PubMed Web of Science ®Google Scholar
• Patil PA, Blakely AM, Lombardo KA, et al. Expression of PD-L1, indoleamine 2,3-dioxygenase and the immune microenvironment in gastric adenocarcinoma. Histopathology. 2018;73(1):124–136. doi:10.1111/his.13504
   PubMed Web of Science ®Google Scholar
• Yu X, Jin J, Zheng Y, et al. GBP5 drives malignancy of glioblastoma via the Src/ERK1/2/MMP3 pathway. Cell Death Dis. 2021;12(2):203. doi:10.1038/s41419-021-03492-3
   PubMed Web of Science ®Google Scholar
• Qian J, Wang C, Wang B, et al. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy. J Neuroinflammation. 2018;15(1):290. doi:10.1186/s12974-018-1330-2
   PubMed Web of Science ®Google Scholar
• Friedman K, Brodsky AS, Lu S, et al. Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. Mod Pathol. 2016;29(5):528–541. doi:10.1038/modpathol.2016.54
   PubMed Web of Science ®Google Scholar
• He Q-L, Jiang H-X, Zhang X-L, Qin S-Y. Relationship between a 7-mRNA signature of the pancreatic adenocarcinoma microenvironment and patient prognosis (a STROBE-compliant article). Medicine. 2020;99(29):e21287. doi:10.1097/MD.0000000000021287
   PubMed Web of Science ®Google Scholar
• George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524(7563):47–53. doi:10.1038/nature14664
   PubMed Web of Science ®Google Scholar
• Jiang L, Huang J, Higgs BW, et al. Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer. PLoS Genet. 2016;12(4):e1005895. doi:10.1371/journal.pgen.1005895
   PubMed Web of Science ®Google Scholar
• Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38. doi:10.5114/pg.2018.80001
   PubMed Web of Science ®Google Scholar
• Jiang P, Gu S, Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550–1558. doi:10.1038/s41591-018-0136-1
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Liu D, Schilling B, Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916–1927. doi:10.1038/s41591-019-0654-5
   PubMed Web of Science ®Google Scholar
• Plattner C, Finotello F, Rieder D. Deconvoluting tumor-infiltrating immune cells from RNA-seq data using quanTIseq. Methods Enzymol. 2020;636:261–285. doi:10.1016/bs.mie.2019.05.056
   PubMed Web of Science ®Google Scholar
• Becht E, Giraldo NA, Lacroix L, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17(1):218. doi:10.1186/s13059-016-1070-5
   PubMed Web of Science ®Google Scholar
• Racle J, Gfeller D. EPIC: a tool to estimate the proportions of different cell types from bulk gene expression data. Methods Mol Biol. 2020;2120:233–248. doi:10.1007/978-1-0716-0327-7_17
   PubMedGoogle Scholar
• Lin A, Qi C, Wei T, et al. CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer. Brief Bioinform. 2022;23(3). doi:10.1093/bib/bbac129
   Web of Science ®Google Scholar
• Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for gene set enrichment analysis. Bioinformatics. 2007;23(23):3251–3253. doi:10.1093/bioinformatics/btm369
   PubMed Web of Science ®Google Scholar
• Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14(1):7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27(12):1739–1740. doi:10.1093/bioinformatics/btr260
   PubMed Web of Science ®Google Scholar
• Leal T, Wang Y, Dowlati A, et al. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. J Clin Oncol. 2020;38(suppl15):9000. doi:10.1200/JCO.2020.38.15_suppl.9000
   Google Scholar
• Reck M, Luft A, Szczesna A, et al. Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol. 2016;34(31):3740–3748. doi:10.1200/JCO.2016.67.6601
   PubMed Web of Science ®Google Scholar
• Liang C, Fan J, Liang C, Guo J. Identification and validation of a pyroptosis-related prognostic model for gastric cancer. Front Genet. 2021;12:699503. doi:10.3389/fgene.2021.699503
   PubMed Web of Science ®Google Scholar
• Hachim MY, Hachim IY, Talaat IM, Yakout NM, Hamoudi R. M1 polarization markers are upregulated in basal-like breast cancer molecular subtype and associated with favorable patient outcome. Front Immunol. 2020;11:560074. doi:10.3389/fimmu.2020.560074
   PubMed Web of Science ®Google Scholar
• Cheng S-W, Chen P-C, Lin M-H, Ger T-R, Chiu H-W, Lin Y-F. GBP5 repression suppresses the metastatic potential and PD-L1 expression in triple-negative breast cancer. Biomedicines. 2021;9(4):371. doi:10.3390/biomedicines9040371
   PubMed Web of Science ®Google Scholar
• Wang Q, Wang X, Liang Q, et al. Distinct prognostic value of mRNA expression of guanylate-binding protein genes in skin cutaneous melanoma. Oncol Lett. 2018;15(5):7914–7922. doi:10.3892/ol.2018.8306
   PubMed Web of Science ®Google Scholar
• Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659–702. doi:10.1146/annurev-immunol-032713-120145
   PubMed Web of Science ®Google Scholar
• Yan Y, Zheng L, Du Q, et al. Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett. 2021;506:95–106. doi:10.1016/j.canlet.2021.03.002
   PubMed Web of Science ®Google Scholar
• Hsu C-L, Ou D-L, Bai L-Y, et al. Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma. Liver Cancer. 2021;10(4):346–359. doi:10.1159/000515305
   PubMed Web of Science ®Google Scholar
• Inoue H, Park J-H, Kiyotani K, et al. Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology. 2016;5(9):e1204507. doi:10.1080/2162402X.2016.1204507
   PubMed Web of Science ®Google Scholar
• Ruf M, Moch H, Schraml P. Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma. Oncoimmunology. 2015;4(12):e1049805. doi:10.1080/2162402X.2015.1049805
   PubMed Web of Science ®Google Scholar
• Willeaume V, Kruys V, Mijatovic T, Huez G. Tumor necrosis factor-alpha production induced by viruses and by lipopolysaccharides in macrophages: similarities and differences. J Inflamm. 1995;46(1):1–12.
   PubMedGoogle Scholar
• de Silva DG, Mendis LN, Sheron N, et al. TNF alpha in stool as marker of intestinal inflammation. Lancet. 1992;340(8815):372. doi:10.1016/0140-6736(92)91446-f
   PubMed Web of Science ®Google Scholar
• Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 1998;95(2):570–575. doi:10.1073/pnas.95.2.570
   PubMed Web of Science ®Google Scholar
• Colonna M. innate lymphoid cells: diversity, plasticity, and unique functions in immunity. Immunity. 2018;48(6):1104–1117. doi:10.1016/j.immuni.2018.05.013
   PubMed Web of Science ®Google Scholar
• Zhang C, Targeting LY. NK cell checkpoint receptors or molecules for cancer immunotherapy. Front Immunol. 2020;11:1295. doi:10.3389/fimmu.2020.01295
   PubMed Web of Science ®Google Scholar
• Helmink BA, Reddy SM, Gao J, et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577(7791):549–555. doi:10.1038/s41586-019-1922-8
   PubMed Web of Science ®Google Scholar
• Cabrita R, Lauss M, Sanna A, et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature. 2020;577(7791):561–565. doi:10.1038/s41586-019-1914-8
   PubMed Web of Science ®Google Scholar
• Daud AI, Loo K, Pauli ML, et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest. 2016;126(9):3447–3452. doi:10.1172/JCI87324
   PubMed Web of Science ®Google Scholar